Regencell Bioscience Holdings Limited (NASDAQ:RGC) saw its shares gap up significantly before the opening bell on Friday, jumping from Thursday’s close of $21.00 to an opening price of $22.04. By mid‐morning trading the stock was last quoted at $22.12 on a volume of 25,705 shares, marking one of the largest one‐day percentage moves for the large‐cap biotech over the past quarter.

Despite the recent price spike, analyst sentiment on RGC remains subdued. Weiss Ratings reiterated a “sell (e+)” rating on December 29th, and MarketBeat.com data shows the lone available consensus rating is also a Sell. No new upgrades or price‐target hikes were reported this week, leaving the average estimate on hold despite the Friday rally.

During Q2 and Q3, several hedge funds and institutional investors reshaped their stakes in RGC. Notably, Geode Capital Management increased its position by 5,637.5%, boosting its holding to 391,066 shares valued at approximately $6.66 million. Squarepoint Ops LLC initiated a new position worth $1.70 million, BNP Paribas Financial Markets added $768,000, XTX Topco Ltd invested $598,000, and Y Intercept Hong Kong Ltd took on $222,000 of equity. Collectively, institutions now own just 0.13% of Regencell’s outstanding shares.

Founded in 2014 and headquartered in Causeway Bay, Hong Kong, Regencell Bioscience specializes in Traditional Chinese Medicine (TCM)–based therapies targeting neurocognitive disorders. Its lead programs are in ADHD and autism spectrum disorder, with ongoing preclinical studies and planned Phase II trials. The company’s 50‐day moving average stands at $16.14, and its 200‐day moving average is $16.51, underscoring the stock’s recent breakout from longer‐term trading ranges.